Lipocine initiates BLOOM Phase 3 trial of LPCN 1154 oral brexanolone for postpartum depressionPUBT·Sep 14 at 10:16 AMLPCN-0.45%
Lipocine raises sales agent fee to up to 3% under equity distribution agreementPUBT·Sep 11 at 10:11 AMLPCN-0.45%
Lipocine files Form 3 initial beneficial ownership statement for director Michael GrissingerPUBT·Aug 7 at 08:08 PMLPCN-0.45%
Lipocine Q2 2026 earnings: Missing license revenue drives top-line declineTradingKey·Aug 5 at 07:18 AMLPCN-0.45%
LPCN: Net loss widened in Q2 2026, but cash position improved and TLANDO royalties increasedQuartr·Aug 4 at 10:16 AMLPCN-0.45%
Lipocine Q2 FY26 net loss widens to $2.6 million; revenue drops to $190,099PUBT·Aug 4 at 10:15 AMLPCN-0.45%
Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q SummaryTradingView·Aug 4 at 10:11 AMLPCN-0.45%
